💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tafenoquine

CHEMBL298470 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
463.5 g/mol
LogP
5.4
Phase
4

Tafenoquine is a long-acting 8-aminoquinoline antimalarial drug used for radical cure of Plasmodium vivax malaria (preventing relapse from hypnozoites) and for malaria chemoprophylaxis, with a half-life of approximately 14 days allowing single-dose treatment for vivax radical cure. Its mechanism involves generation of reactive oxygen species that are selectively toxic to Plasmodium parasites, particularly the dormant liver-stage hypnozoites responsible for P. vivax relapse. Like primaquine, it can cause hemolytic anemia in patients with G6PD deficiency.

분자량

463.5000 g/mol

LogP

5.40

TPSA

78.60 Ų

리핀스키 5의 법칙

통과

치료 영역

Infectious Disease Malaria

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H28F3N3O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
회전 가능 결합

                        
9

                    

                    
                    
                    

                        
무거운 원자

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
Tafenoquine is a long-acting 8-aminoquinoline antimalarial drug used for radical cure of Plasmodium vivax malaria (preventing relapse from hypnozoites) and for malaria chemoprophylaxis, with a half-life of approximately 14 days allowing single-dose treatment for vivax radical cure. Its mechanism involves generation of reactive oxygen species that are selectively toxic to Plasmodium parasites, particularly the dormant liver-stage hypnozoites responsible for P. vivax relapse. Like primaquine, it can cause hemolytic anemia in patients with G6PD deficiency.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Tafenoquine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL298470.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 115358.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.